Sihuan Pharmaceutical has unveiled plans to adopt a 2026 Share Incentive Scheme, aiming to strengthen its long-term talent incentives and align employee interests with the Group’s strategic goals in medical aesthetics. The Board approved the proposal on 8 May 2026.

The new scheme, framed under Chapter 17 of the Hong Kong Listing Rules, is designed to:

• Attract, retain and motivate key management, R&D and core business personnel in the medical aesthetics segment. • Foster innovation, accountability and engagement in product development, compliance, branding and market expansion. • Support Sihuan Pharmaceutical’s ambition to become a globally leading, nationally renowned medical aesthetics and healthcare company.

Implementation is contingent on two conditions: 1. Shareholder approval at an upcoming general meeting. 2. Stock Exchange clearance for listing and trading of any new shares issued under the awards.

Upon the scheme’s effectiveness, no further options will be granted under the Share Option Scheme adopted in October 2017. Options already granted under that plan will remain exercisable according to existing terms. The 2022 Share Award Scheme, which involves no new share issuance or treasury share transfers, remains unaffected.

A circular detailing the 2026 Share Incentive Scheme’s principal terms and the general meeting notice will be published and dispatched in accordance with Listing Rule requirements.